Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.
Primary MMRD is more common than previously reported in gliomas in children, adolescents, and young adults, is enriched in specific molecular subgroups, and is associated…
Come together to commemorate oncology nursing’s rich history and be a part of the future of cancer care at the 50th Annual ONS Congress ®!…
Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone…
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a…
